open access

Vol 68, No 4 (2017)
Original paper
Published online: 2017-05-26
Submitted: 2016-04-28
Accepted: 2016-06-09
Get Citation

Correlations between 10-year risk of death from cardiovascular diseases

Anna Kawińska-Hamala, Andrzej Kawiński, Krzysztof Stanek, Michał Stuss, Ewa Sewerynek
DOI: 10.5603/EP.a2017.0030
·
Pubmed: 28660987
·
Endokrynologia Polska 2017;68(4):390-397.

open access

Vol 68, No 4 (2017)
Original Paper
Published online: 2017-05-26
Submitted: 2016-04-28
Accepted: 2016-06-09

Abstract

Introduction: Osteoporosis and cardiovascular diseases (CVD) are more common in the elderly population and have similar risk factors.

The goal was an evaluation of the correlation between 10-year risk of death from CVD and 10-year bone fracture risk (FRAX).

Material and methods: A total of 79 patients of the Regional Centre of Menopause and Osteoporosis of the Military Teaching Hospital in Lodz (Poland), aged 50–83 years, consulted for osteoporosis were divided into two groups: study group — with osteoporosis (O; T-score ≤ –2.5 SD) and control — without osteoporosis (T-sc > –2.5). Bone mineral density was evaluated by densitometric scanning of spine (L2-L4 T-score) and/or femoral neck (Neck T-score) and/or total hip (Total Hip T-score). Total cholesterol (TC), fasting glucose, arterial blood pressure, medical history, and family history were obtained. The risk of fatal-CVD was assessed by Euro Heart Score (EHS), and major osteoporotic (MOFR) and hip fracture risk (HFR) by the FRAX scale.

Results: 80% of the patients (32/40) with osteoporosis and 51% (20/39) of the patients without osteoporosis revealed a HeartScore ≥ 5%. There was correlation in the group of all patients between EHS and Neck T-score (p < 0.05; Spearman rank correlation coefficient (Rs) = –0.3806), L2-L4 T-score (p < 0.05; Rs = –0.2891), and Total Hip T-score (p < 0.005; Rs = –0.3561), and in the control group — between EHS and Neck T-score (p < 0.05; Rs = –0.3502). There was a 2.33% difference between the average EHS level to the disadvantage of patients with osteoporosis (p < 0.05). EHS positively correlated with MOFR (p < 0.001) and HFR (p < 0.001) in the whole study popula­tion and with MOFR (p < 0.05) and HFR (p < 0.01) in the group of osteoporotic patients. There were differences between groups in TC (p < 0.001) and BMI (p < 0.001) levels.

Conclusions: The 10-year risk of fatal-CVD correlated with osteoporosis and with the 10-year osteoporotic fracture risk. This conclusion may help identify patients who require extended cardiotherapy protocols.

Abstract

Introduction: Osteoporosis and cardiovascular diseases (CVD) are more common in the elderly population and have similar risk factors.

The goal was an evaluation of the correlation between 10-year risk of death from CVD and 10-year bone fracture risk (FRAX).

Material and methods: A total of 79 patients of the Regional Centre of Menopause and Osteoporosis of the Military Teaching Hospital in Lodz (Poland), aged 50–83 years, consulted for osteoporosis were divided into two groups: study group — with osteoporosis (O; T-score ≤ –2.5 SD) and control — without osteoporosis (T-sc > –2.5). Bone mineral density was evaluated by densitometric scanning of spine (L2-L4 T-score) and/or femoral neck (Neck T-score) and/or total hip (Total Hip T-score). Total cholesterol (TC), fasting glucose, arterial blood pressure, medical history, and family history were obtained. The risk of fatal-CVD was assessed by Euro Heart Score (EHS), and major osteoporotic (MOFR) and hip fracture risk (HFR) by the FRAX scale.

Results: 80% of the patients (32/40) with osteoporosis and 51% (20/39) of the patients without osteoporosis revealed a HeartScore ≥ 5%. There was correlation in the group of all patients between EHS and Neck T-score (p < 0.05; Spearman rank correlation coefficient (Rs) = –0.3806), L2-L4 T-score (p < 0.05; Rs = –0.2891), and Total Hip T-score (p < 0.005; Rs = –0.3561), and in the control group — between EHS and Neck T-score (p < 0.05; Rs = –0.3502). There was a 2.33% difference between the average EHS level to the disadvantage of patients with osteoporosis (p < 0.05). EHS positively correlated with MOFR (p < 0.001) and HFR (p < 0.001) in the whole study popula­tion and with MOFR (p < 0.05) and HFR (p < 0.01) in the group of osteoporotic patients. There were differences between groups in TC (p < 0.001) and BMI (p < 0.001) levels.

Conclusions: The 10-year risk of fatal-CVD correlated with osteoporosis and with the 10-year osteoporotic fracture risk. This conclusion may help identify patients who require extended cardiotherapy protocols.

Get Citation

Keywords

osteoporosis; cardiovascular diseases; fracture risk; fatal CVD; Euro Heart Score

About this article
Title

Correlations between 10-year risk of death from cardiovascular diseases

Journal

Endokrynologia Polska

Issue

Vol 68, No 4 (2017)

Article type

Original paper

Pages

390-397

Published online

2017-05-26

DOI

10.5603/EP.a2017.0030

Pubmed

28660987

Bibliographic record

Endokrynologia Polska 2017;68(4):390-397.

Keywords

osteoporosis
cardiovascular diseases
fracture risk
fatal CVD
Euro Heart Score

Authors

Anna Kawińska-Hamala
Andrzej Kawiński
Krzysztof Stanek
Michał Stuss
Ewa Sewerynek

References (24)
  1. Cepollaro C, Monaco R, Marcucci G. Cosegregation of cardiovascular diseases and osteoporosis: instrumental diagnosis. Clin Cases Miner Bone Metab. 2008; 5(1): 40–44.
  2. Danilevicius CF, Lopes JB, Pereira RMR. Bone metabolism and vascular calcification. Braz J Med Biol Res. 2007; 40(4): 435–442.
  3. Masugata H, Senda S, Inukai M, et al. Association between Bone Mineral Density and Arterial Stiffness in Hypertensive Patients. Tohoku J Exp Med. 2011; 223(2): 85–90.
  4. Rubin MR, Silverberg SJ. Vascular calcification and osteoporosis--the nature of the nexus. J Clin Endocrinol Metab. 2004; 89(9): 4243–4245.
  5. Shen C, Deng J, Zhou R, et al. Relation Between Bone Mineral Density, Bone Loss and the Risk of Cardiovascular Disease in a Chinese Cohort. The American Journal of Cardiology. 2012; 110(8): 1138–1142.
  6. Yesil Y, Ulger Z, Halil M, et al. Coexistence of osteoporosis (OP) and coronary artery disease (CAD) in the elderly: it is not just a by chance event. Arch Gerontol Geriatr. 2012; 54(3): 473–476.
  7. Wagenaar P. Osteoporosis: a cardiovascular risk factor equivalent to type 2 diabetes. Cardiovasc J Afr. 2010; 21(5): 295.
  8. Meier C, Kränzlin ME. Calcium supplementation, osteoporosis and cardiovascular disease. Swiss Med Wkly. 2011; 141: w13260.
  9. Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008; 5(1): 19–34.
  10. Makovey J, Macara M, Chen JS, et al. High osteoporotic fracture risk and CVD risk co-exist in postmenopausal women. Bone. 2013; 52(1): 120–125.
  11. Tankó LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20(11): 1912–1920.
  12. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999; 106(3): 273–278.
  13. Lloyd-Jones DM. Cardiovascular Risk Prediction: Basic Concepts, Current Status, and Future Directions. Circulation. 2010; 121(15): 1768–1777.
  14. Perk J, De Ba, Helmut G, et al. Europejskie wytyczne dotyczące zapobiegania chorobom serca i naczyń w praktyce klinicznej na 2012 rok. Kardiol Pol. 2012; 70(supl. I): 1–100.
  15. Goncerz G. Polskie zalecenia postępowania diagnostycznego i leczniczego w osteoporozie – podsumowanie aktualizacji 2013. Med Prakt wyd specj Reumatologia. 2013; 1: 33–46.
  16. Gierch M, Gierch J, Junik R. The evlution of lipid profile in ptients with metbolic syndrome ccording to the crdiovsculr risk clculted on the bsis of SCORE chrt. Endokrynol Pol. 2016 [Epub hed of print] doi: 10. 5603/EP a. 2016; 0020.
  17. Sewerynek E, Stuss M, Sewerynek E, et al. Bisphosphonates and the risk of atrial fibrillation. Endokrynol Pol. 2011; 62(1): 93–96.
  18. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM. 2005; 98(7): 467–484.
  19. Spirini D, Rini GB, Di St, et al. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner and Bone Metab. 2014; 11(2): 117–119.
  20. Miazgowski T, Krzyzanowska-Swiniarska B, Ogonowski J, et al. [Does type 2 diabetes predispose to osteoporotic bone fractures?]. Endokrynol Pol. 2008; 59(3): 224–229.
  21. Pluskiewicz W, Adamczyk P, Czekajło A, et al. Falls in RAC-OST-POL Study: epidemiological study in postmenopausal women aged over 55 years. Endokrynol Pol. 2016; 67(2): 185–189.
  22. Samelson EJ, Cupples LA, Hannan MT, et al. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. Bone. 2004; 34(3): 557–561.
  23. Lello S, Capozzi A, Scambia G. Osteoporosis and cardiovascular disease: an update. Gynecol Endocrinol. 2015; 31(8): 590–594.
  24. Garanty-Bogacka B, Syrenicz M, Rać M, et al. Association between serum osteocalcin, adiposity and metabolic risk in obese children and adolescents. Endokrynol Pol. 2013; 64(5): 346–352.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl